간질 치료제 시장 규모는 향후 수년간 강력한 성장세를 보일 것으로 예상되며, 2029년에는 연평균 7.9%의 연평균 복합 성장률(CAGR)로 151억 1,000만 달러에 달할 것으로 예상됩니다. 예측 기간 중의 성장은 맞춤형 의료의 확대, 새로운 약물전달 방법의 채택, 디지털 헬스 솔루션의 출현, R&D 투자 증가, AI와 ML의 통합에 기인할 것으로 보입니다. 예측 기간의 주요 동향으로는 병용요법으로의 전환, 원격의료의 부상, 약물 내성 간질에 대한 집중, 유전자 검사의 통합, 웨어러블 기기의 활용 등을 꼽을 수 있습니다.
간질 환자 수 증가가 예상에 따라 간질 치료제 시장은 향후 수년간 성장할 것으로 예상됩니다. 간질은 다양한 중증도의 반복적인 발작이 특징인 신경질환으로 일상생활에 큰 영향을 미칠 수 있는 질환입니다. 이 질환은 고령층에서 더 많이 발생하며, 외상성 뇌손상(TBI), 뇌졸중, 뇌종양, 기타 신경질환을 경험한 사람은 간질 발병 위험이 높습니다. 간질 치료제는 뇌의 전기적 활동을 안정화시켜 발작의 빈도와 심각성을 감소시켜 간질 관리 및 조절에 도움을 줍니다. 예를 들어 세계보건기구(WHO)의 2024년 2월 보고서에 따르면 전 세계에서 연간 약 500만 명이 간질 진단을 받고 있습니다. 고소득 국가에서는 인구 10만 명당 연간 49명의 환자가 보고되고 있지만, 중저소득 국가에서는 10만 명당 139명의 환자가 보고되고 있습니다. 이처럼 간질 환자 수 증가가 간질 치료제 시장 성장의 원동력이 되고 있습니다.
간질 치료제 시장의 주요 업체들은 발작 조절을 강화하고 환자의 삶의 질을 향상시킬 수 있는 혁신적인 치료법 개발에 주력하고 있습니다. 이러한 혁신적인 치료법에는 새로운 약물 제제, 첨단 신경 자극 기술, 환자 맞춤형 정밀의료 접근법, 유전자 치료, 발작 감지 및 개입을 위한 폐쇄 루프 시스템 등의 신기술이 포함될 수 있습니다. 예를 들어 2024년 1월 인도 제약회사 악멘티스 헬스케어는 1세 이상의 레녹스-가스토 증후군(LGS), 드라베 증후군, 결절성 경화증 복합체(TSC)에 따른 발작을 치료하기 위해 특별히 처방된 대마(CBD) 제제인 클라세피(Kracepi)를 출시했습니다.를 발표했습니다. 인도 의약품감독청(DCGI)의 승인을 받은 크라세피는 특히 기존 항간질약이 효과가 없는 환자에서 간질 발작 감소에 효과가 있는 것으로 입증되었습니다.
목차
제1장 개요
제2장 시장의 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 신형 코로나바이러스 및 경기회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
- 세계라고 나 치료제 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
- 최종 용도 산업의 분석
- 세계의 간질 치료제 시장 : 성장률 분석
- 세계의 간질 치료제 시장 실적 : 규모와 성장, 2019-2024
- 세계의 간질 치료제 시장 예측 : 규모와 성장, 2024-2029, 2034F
- 세계라고 나 치료제 TAM(Total Addressable Market)
제6장 시장 세분화
- 세계의 간질 치료제 시장 : 발작 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 국소 발작
- 전신 발작
- 비간질 발작
- 세계의 간질 치료제 시장 : 세대별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 제1세대 항간질약
- 제2세대 항간질약
- 제3세대 항간질약
- 세계의 간질 치료제 시장 : 투여 경로별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 경구
- 정맥내
- 근육내
- 세계의 간질 치료제 시장 : 유통 채널별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 드러그스토어와 약국
- 병원 약국
- 세계의 간질 치료제 시장, 초점 발작의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 단순 초점 발작
- 복잡 초점 발작
- 세계의 간질 치료제 시장, 전반 발작의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 강직 방세 발작(대발작)
- 결신발작(소발작)
- 근육 경련 발작
- 강직 발작
- 탈진 발작
- 세계의 간질 치료제 시장, 비간질성 발작의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 심인성 비간질성 발작(PNES)
- 기능성 발작
제7장 지역별·국가별 분석
- 세계의 간질 치료제 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 세계의 간질 치료제 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
- 간질 치료제 시장 : 경쟁 구도
- 간질 치료제 시장 : 기업 개요
- Pfizer Inc Overview, Products and Services, Strategy and Financial Analysis
- SK Biopharmaceuticals Overview, Products and Services, Strategy and Financial Analysis
- Sanofi Overview, Products and Services, Strategy and Financial Analysis
- Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
- Novartis AG Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 대기업과 혁신적 기업
- GlaxoSmithKline plc
- H. Lundbeck
- Viatris
- Otsuka America Pharmaceutical Inc
- Bausch Health Companies Inc
- UCB S.A
- Sun Pharmaceutical Industries Ltd
- Eisai Co Ltd
- Sumitomo Pharma Co Ltd
- Jazz Pharmaceuticals plc
- Dr. Reddy's Laboratories Ltd
- Angelini S.p.a
- Amneal Pharmaceuticals
- Alkem Laboratories
- Sunovion Pharmaceuticals Inc
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 합병과 인수
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
- 간질 치료제 시장 2029 : 새로운 기회를 제공하는 국가
- 간질 치료제 시장 2029 : 새로운 기회를 제공하는 부문
- 간질 치료제 시장 2029 : 성장 전략
제36장 부록
KSA
Epilepsy drugs, also referred to as antiepileptic drugs (AEDs) or antiseizure medications, are utilized to manage and control seizures in individuals diagnosed with epilepsy. Epilepsy, a neurological disorder characterized by recurring seizures, manifests in various types, severities, and frequencies. These medications operate by stabilizing electrical activity within the brain, thereby decreasing the likelihood of seizures.
The primary types of seizures targeted by epilepsy drugs include focal seizures, generalized seizures, and non-epileptic seizures. Focal seizures originate in a specific area of the brain, leading to localized symptoms. These drugs are categorized into first-generation, second-generation, and third-generation anti-epileptics, administered through routes such as oral, intravenous, and intra-muscular, and are distributed through drug stores, retail pharmacies, and hospital pharmacies.
The epilepsy drugs research report is one of a series of new reports from The Business Research Company that provides epilepsy drugs market statistics, including the epilepsy drugs industry's global market size, regional shares, competitors with an epilepsy drugs market share, detailed epilepsy drugs market segments, market trends and opportunities, and any further data you may need to thrive in the epilepsy drugs industry. This epilepsy drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The epilepsy drugs market size has grown strongly in recent years. It will grow from $10.34 billion in 2024 to $11.17 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to development of antiepileptic drugs, advancements in diagnostic techniques, increased understanding of epilepsy's neurological basis, growing demand for epilepsy treatment, and regulatory approvals for new medications.
The epilepsy drugs market size is expected to see strong growth in the next few years. It will grow to $15.11 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to expansion of personalized medicine, adoption of novel drug delivery methods, emergence of digital health solutions, increased investment in R&D, and integration of AI and ML. Major trends in the forecast period include shift towards combination therapies, rise of telemedicine, focus on drug-resistant epilepsy, integration of genetic testing, and utilization of wearable devices.
The anticipated increase in the number of people affected by epilepsy is expected to drive the growth of the epilepsy drug market in the coming years. Epilepsy is a neurological disorder characterized by recurrent seizures of varying severity, which can significantly impact daily life. This condition is more prevalent among older age groups, and individuals who have experienced traumatic brain injuries (TBIs), strokes, brain tumors, or other neurological conditions are at higher risk of developing epilepsy. Epilepsy drugs function by stabilizing electrical activity in the brain, thereby reducing the frequency and severity of seizures and aiding in the management and control of epilepsy. For instance, as per the February 2024 report from the World Health Organization, approximately 5 million individuals worldwide receive an epilepsy diagnosis annually. High-income countries report an estimated 49 cases per 100,000 people annually, while in low- and middle-income nations, this rate can soar to 139 cases per 100,000. Thus, the increasing number of people affected by epilepsy is a driving force behind the growth of the epilepsy drug market.
Key players in the epilepsy drug market are concentrating on developing innovative treatments to enhance seizure control and improve patient quality of life. These innovative treatments may involve novel drug formulations, advanced neurostimulation techniques, precision medicine approaches tailored to individual patients, gene therapies, and emerging technologies such as closed-loop systems for seizure detection and intervention. For example, in January 2024, Akumentis Healthcare, an India-based pharmaceutical company, introduced Clasepi, a prescription cannabidiol (CBD) drug specifically formulated to treat seizures associated with Lennox-Gastaut Syndrome (LGS), Dravet Syndrome, or Tuberous Sclerosis Complex (TSC) in patients aged 1 year and older. Approved by the Drug Controller General of India (DCGI), Clasepi has demonstrated efficacy in reducing seizures, particularly in cases where conventional anti-seizure medications have been ineffective.
In April 2024, Harmony Biosciences, a US-based biopharmaceutical company, acquired Epygenix Therapeutics Inc for an undisclosed amount. This acquisition strengthens Harmony Biosciences' epilepsy treatment portfolio, expands its market reach, and enhances its research and development capabilities. Epygenix Therapeutics Inc, based in the US, is a precision medicine-based biopharmaceutical company focused on developing drugs to treat rare and intractable forms of genetic epilepsy.
Major companies operating in the epilepsy drugs market are Pfizer Inc, SK Biopharmaceuticals, Sanofi, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, H. Lundbeck, Viatris, Otsuka America Pharmaceutical Inc, Bausch Health Companies Inc, UCB S.A, Sun Pharmaceutical Industries Ltd, Eisai Co Ltd, Sumitomo Pharma Co Ltd, Jazz Pharmaceuticals plc, Dr. Reddy's Laboratories Ltd, Angelini S.p.a, Amneal Pharmaceuticals, Alkem Laboratories, Sunovion Pharmaceuticals Inc, Upsher-Smith, Zogenix, Neurelis Inc
North America was the largest region in the epilepsy drugs market in 2024. The regions covered in the epilepsy drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the epilepsy drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The epilepsy drugs market consists of sales of carbamazepine, lamotrigine, phenobarbital, phenytoin, and valproic acid. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Epilepsy Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on epilepsy drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for epilepsy drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The epilepsy drugs market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Seizure Type: Focal Seizures; Generalized Seizures; Non-Epileptic Seizures
- 2) By Generation Type: First Generation Anti-Epileptics; Second Generation Anti-Epileptics; Third Generation Anti-Epileptics
- 3) By Route Of Administration: Oral; Intravenous; Intra-Muscular
- 4) By Distribution Channel: Drug Stores And Retail Pharmacies; Hospital Pharmacies
- Subsegments:
- 1) By Focal Seizures: Simple Focal Seizures; Complex Focal Seizures
- 2) By Generalized Seizures: Tonic-Clonic Seizures (Grand Mal); Absence Seizures (Petit Mal); Myoclonic Seizures; Tonic Seizures; Atonic Seizures
- 3) By Non-Epileptic Seizures: Psychogenic Non-Epileptic Seizures (PNES); Functional Seizures
- Companies Mentioned: Pfizer Inc; SK Biopharmaceuticals; Sanofi; Abbott Laboratories; Novartis AG
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Epilepsy Drugs Market Characteristics
3. Epilepsy Drugs Market Trends And Strategies
4. Epilepsy Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market
5. Global Epilepsy Drugs Growth Analysis And Strategic Analysis Framework
- 5.1. Global Epilepsy Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Epilepsy Drugs Market Growth Rate Analysis
- 5.4. Global Epilepsy Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Epilepsy Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Epilepsy Drugs Total Addressable Market (TAM)
6. Epilepsy Drugs Market Segmentation
- 6.1. Global Epilepsy Drugs Market, Segmentation By Seizure Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Focal Seizures
- Generalized Seizures
- Non-Epileptic Seizures
- 6.2. Global Epilepsy Drugs Market, Segmentation By Generation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- First Generation Anti-Epileptics
- Second Generation Anti-Epileptics
- Third Generation Anti-Epileptics
- 6.3. Global Epilepsy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oral
- Intravenous
- Intra-Muscular
- 6.4. Global Epilepsy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Drug Stores And Retail Pharmacies
- Hospital Pharmacies
- 6.5. Global Epilepsy Drugs Market, Sub-Segmentation Of Focal Seizures, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Simple Focal Seizures
- Complex Focal Seizures
- 6.6. Global Epilepsy Drugs Market, Sub-Segmentation Of Generalized Seizures, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Tonic-Clonic Seizures (Grand Mal)
- Absence Seizures (Petit Mal)
- Myoclonic Seizures
- Tonic Seizures
- Atonic Seizures
- 6.7. Global Epilepsy Drugs Market, Sub-Segmentation Of Non-Epileptic Seizures, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Psychogenic Non-Epileptic Seizures (PNES)
- Functional Seizures
7. Epilepsy Drugs Market Regional And Country Analysis
- 7.1. Global Epilepsy Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Epilepsy Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Epilepsy Drugs Market
- 8.1. Asia-Pacific Epilepsy Drugs Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Epilepsy Drugs Market, Segmentation By Seizure Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Epilepsy Drugs Market, Segmentation By Generation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Epilepsy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Epilepsy Drugs Market
- 9.1. China Epilepsy Drugs Market Overview
- 9.2. China Epilepsy Drugs Market, Segmentation By Seizure Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Epilepsy Drugs Market, Segmentation By Generation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Epilepsy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Epilepsy Drugs Market
- 10.1. India Epilepsy Drugs Market, Segmentation By Seizure Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Epilepsy Drugs Market, Segmentation By Generation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Epilepsy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Epilepsy Drugs Market
- 11.1. Japan Epilepsy Drugs Market Overview
- 11.2. Japan Epilepsy Drugs Market, Segmentation By Seizure Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Epilepsy Drugs Market, Segmentation By Generation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Epilepsy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Epilepsy Drugs Market
- 12.1. Australia Epilepsy Drugs Market, Segmentation By Seizure Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Epilepsy Drugs Market, Segmentation By Generation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Epilepsy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Epilepsy Drugs Market
- 13.1. Indonesia Epilepsy Drugs Market, Segmentation By Seizure Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Epilepsy Drugs Market, Segmentation By Generation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Epilepsy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Epilepsy Drugs Market
- 14.1. South Korea Epilepsy Drugs Market Overview
- 14.2. South Korea Epilepsy Drugs Market, Segmentation By Seizure Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Epilepsy Drugs Market, Segmentation By Generation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Epilepsy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Epilepsy Drugs Market
- 15.1. Western Europe Epilepsy Drugs Market Overview
- 15.2. Western Europe Epilepsy Drugs Market, Segmentation By Seizure Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Epilepsy Drugs Market, Segmentation By Generation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Epilepsy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Epilepsy Drugs Market
- 16.1. UK Epilepsy Drugs Market, Segmentation By Seizure Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Epilepsy Drugs Market, Segmentation By Generation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Epilepsy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Epilepsy Drugs Market
- 17.1. Germany Epilepsy Drugs Market, Segmentation By Seizure Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Epilepsy Drugs Market, Segmentation By Generation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Epilepsy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Epilepsy Drugs Market
- 18.1. France Epilepsy Drugs Market, Segmentation By Seizure Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Epilepsy Drugs Market, Segmentation By Generation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Epilepsy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Epilepsy Drugs Market
- 19.1. Italy Epilepsy Drugs Market, Segmentation By Seizure Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Epilepsy Drugs Market, Segmentation By Generation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Epilepsy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Epilepsy Drugs Market
- 20.1. Spain Epilepsy Drugs Market, Segmentation By Seizure Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Epilepsy Drugs Market, Segmentation By Generation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Epilepsy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Epilepsy Drugs Market
- 21.1. Eastern Europe Epilepsy Drugs Market Overview
- 21.2. Eastern Europe Epilepsy Drugs Market, Segmentation By Seizure Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Epilepsy Drugs Market, Segmentation By Generation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Epilepsy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Epilepsy Drugs Market
- 22.1. Russia Epilepsy Drugs Market, Segmentation By Seizure Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Epilepsy Drugs Market, Segmentation By Generation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Epilepsy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Epilepsy Drugs Market
- 23.1. North America Epilepsy Drugs Market Overview
- 23.2. North America Epilepsy Drugs Market, Segmentation By Seizure Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Epilepsy Drugs Market, Segmentation By Generation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Epilepsy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Epilepsy Drugs Market
- 24.1. USA Epilepsy Drugs Market Overview
- 24.2. USA Epilepsy Drugs Market, Segmentation By Seizure Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Epilepsy Drugs Market, Segmentation By Generation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Epilepsy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Epilepsy Drugs Market
- 25.1. Canada Epilepsy Drugs Market Overview
- 25.2. Canada Epilepsy Drugs Market, Segmentation By Seizure Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Epilepsy Drugs Market, Segmentation By Generation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Epilepsy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Epilepsy Drugs Market
- 26.1. South America Epilepsy Drugs Market Overview
- 26.2. South America Epilepsy Drugs Market, Segmentation By Seizure Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Epilepsy Drugs Market, Segmentation By Generation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Epilepsy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Epilepsy Drugs Market
- 27.1. Brazil Epilepsy Drugs Market, Segmentation By Seizure Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Epilepsy Drugs Market, Segmentation By Generation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Epilepsy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Epilepsy Drugs Market
- 28.1. Middle East Epilepsy Drugs Market Overview
- 28.2. Middle East Epilepsy Drugs Market, Segmentation By Seizure Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Epilepsy Drugs Market, Segmentation By Generation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Epilepsy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Epilepsy Drugs Market
- 29.1. Africa Epilepsy Drugs Market Overview
- 29.2. Africa Epilepsy Drugs Market, Segmentation By Seizure Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Epilepsy Drugs Market, Segmentation By Generation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Epilepsy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Epilepsy Drugs Market Competitive Landscape And Company Profiles
- 30.1. Epilepsy Drugs Market Competitive Landscape
- 30.2. Epilepsy Drugs Market Company Profiles
- 30.2.1. Pfizer Inc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. SK Biopharmaceuticals Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Sanofi Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
31. Epilepsy Drugs Market Other Major And Innovative Companies
- 31.1. GlaxoSmithKline plc
- 31.2. H. Lundbeck
- 31.3. Viatris
- 31.4. Otsuka America Pharmaceutical Inc
- 31.5. Bausch Health Companies Inc
- 31.6. UCB S.A
- 31.7. Sun Pharmaceutical Industries Ltd
- 31.8. Eisai Co Ltd
- 31.9. Sumitomo Pharma Co Ltd
- 31.10. Jazz Pharmaceuticals plc
- 31.11. Dr. Reddy's Laboratories Ltd
- 31.12. Angelini S.p.a
- 31.13. Amneal Pharmaceuticals
- 31.14. Alkem Laboratories
- 31.15. Sunovion Pharmaceuticals Inc
32. Global Epilepsy Drugs Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Epilepsy Drugs Market
34. Recent Developments In The Epilepsy Drugs Market
35. Epilepsy Drugs Market High Potential Countries, Segments and Strategies
- 35.1 Epilepsy Drugs Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Epilepsy Drugs Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Epilepsy Drugs Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
